[HTML][HTML] Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin α5/β1-FAK/Src axis: A novel strategy for drug application
The application of immune checkpoint inhibitors and FGFR protein tyrosine kinase inhibitors
have made a tremendous breakthrough in bladder cancer therapy. However, inadequate …
have made a tremendous breakthrough in bladder cancer therapy. However, inadequate …
Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin α5/β1-FAK/Src axis: A novel strategy for drug application
Q Wu, P Chen, J Li, Z Lin, Q Zhang… - Pharmacological …, 2023 - pubmed.ncbi.nlm.nih.gov
The application of immune checkpoint inhibitors and FGFR protein tyrosine kinase inhibitors
have made a tremendous breakthrough in bladder cancer therapy. However, inadequate …
have made a tremendous breakthrough in bladder cancer therapy. However, inadequate …
Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin α5/β1-FAK/Src axis: A novel strategy for drug application
Q Wu, P Chen, J Li, Z Lin, Q Zhang, HF Kwok - 2023 - repository.um.edu.mo
The application of immune checkpoint inhibitors and FGFR protein tyrosine kinase inhibitors
have made a tremendous breakthrough in bladder cancer therapy. However, inadequate …
have made a tremendous breakthrough in bladder cancer therapy. However, inadequate …
Inhibition of Bladder Cancer Growth with Homoharringtonine by inactivating integrin α5/β1-FAK/Src axis: A Novel Strategy for Drug Application.
Q Wu, P Chen, J Li, Z Lin, Q Zhang… - Pharmacological …, 2023 - europepmc.org
The application of immune checkpoint inhibitors and FGFR protein tyrosine kinase inhibitors
have made a tremendous breakthrough in bladder cancer therapy. However, inadequate …
have made a tremendous breakthrough in bladder cancer therapy. However, inadequate …